Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker OFAL
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 5, 2026 | OFAL OFA Group | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 29, 2026 | OFAL OFA Group | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Oct 29, 2026 | OFAL OFA Group | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 29, 2026 | OFAL OFA Group | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 9, 2026 | OFAL OFA Group | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Oct 5, 2026 | OFAL OFA Group | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 13, 2026 | OFAL OFA Group | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jul 27, 2026 | OFAL OFA Group | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 23, 2026 | OFAL OFA Group | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jun 12, 2026 | OFAL OFA Group | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 12, 2026 | OFAL OFA Group | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Jun 8, 2026 | OFAL OFA Group | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| May 26, 2026 | OFAL OFA Group | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 26, 2026 | OFAL OFA Group | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 14, 2026 | OFAL OFA Group | 8.01 Other Events | 8-K | 8-K ↗ |
| May 14, 2026 | OFAL OFA Group | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Apr 22, 2026 | OFAL OFA Group | 7.01 Regulation FD Disclosure | 8-K/A | 8-K ↗ |
| Apr 22, 2026 | OFAL OFA Group | 1.01 Entry into a Material Definitive Agreement | 8-K/A | 8-K ↗ |
| Apr 8, 2026 | OFAL OFA Group | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 6, 2026 | OFAL OFA Group | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Apr 6, 2026 | OFAL OFA Group | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 6, 2026 | OFAL OFA Group | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
22 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 3:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances